Share Twitter LinkedIn Facebook Email Jack Stewart, CSO of Soricimed Biopharma discusses SOR-C13, a selective inhibitor of TRPV6, binds with affinity and disrupts how TRPV6 functions. Advertisement
Alcohol Consumption and Cancer Risk: Insights from the 2025 Surgeon Generalโs Advisory Breast Cancer 3 Mins Read
